Key result
Ibutilide safely and successfully terminated symptomatic persistent atrial flutter in a patient during her 24th week of pregnancy.
Why the study?
Does ibutilide safely terminate symptomatic persistent atrial flutter in pregnant patients?
Case Report (n=1)
Does ibutilide safely terminate symptomatic persistent atrial flutter in pregnant patients?
Ibutilide may serve as a safe pharmacological alternative to direct current cardioversion for terminating atrial flutter during pregnancy.
Answers are grounded in this paper and cite their sources.
Should not change practice; this case leaves open ibutilide's role versus cardioversion in pregnancy.
Sustained atrial fibrillation and atrial flutter during pregnancy are uncommon arrhythmias that can significantly complicate normal prenatal care. Direct current external cardioversion is the current method of terminating these arrhythmias. In practice, however, this technique is sometimes considered undesirable by both physician and patients due to the need for deep sedation or anesthesia. In the present study, we describe the use of ibutilide to safely terminate symptomatic persistent atrial flutter in a patient during her 24th week of pregnancy.
No takes yet. Share an insight, caveat, or question.
Burkart et al. (2007) conducted a case report in Symptomatic persistent atrial flutter during pregnancy (n=1). Ibutilide was evaluated on Termination of symptomatic persistent atrial flutter. Ibutilide safely and successfully terminated symptomatic persistent atrial flutter in a patient during her 24th week of pregnancy.
Synapse has enriched 10 related papers. Consider them for comparative context: